Government shutdowns are becoming a more persistent threat; is your IPO ready?

As life sciences companies mature, intellectual property often becomes both their most valuable and most scrutinized asset.

For some biotechs, AI isn’t just a tool; it’s their entire thesis.

As early-stage life sciences companies prepare for their next financing or partnership, intellectual property due diligence is often the first, and most consequential, checkpoint.

Why do some life sciences companies stall between Series B and IPO?

Transitioning from discovery to clinical development marks a defining moment for emerging biotech companies. It’s also a time to consider evolving your IP strategy from protecting ideas to protecting assets.

Publicly sharing clinical results can trigger a range of regulatory and compliance obligations, especially for companies approaching or already in the public markets.

For any life sciences company, a clinical data readout is more than a scientific milestone. It’s a corporate event that can influence investor sentiment and the broader perception of the program.

In this market, the founders who succeed are generally the ones anchored by a strong “why,” a deep sense of humility, and a willingness to take their medicine when reality demands it.

Amid rapid technological advancements and regulatory uncertainty, navigating the life sciences ecosystem can be challenging.

What do life sciences companies need to know about capital markets heading into 2026?